107 related articles for article (PubMed ID: 3106283)
1. Restoration of impaired T cell functions in tumor-bearing mice by the administration of interleukin 1.
Yamashita U; Shirakawa F
Jpn J Cancer Res; 1987 Mar; 78(3):270-8. PubMed ID: 3106283
[TBL] [Abstract][Full Text] [Related]
2. Dysfunction of Ia-positive antigen-presenting cells in tumor-bearing mice.
Yamashita U
Jpn J Cancer Res; 1987 Mar; 78(3):261-9. PubMed ID: 3106282
[TBL] [Abstract][Full Text] [Related]
3. Enhanced induction of tumor-specific Lyt-1+2- T cell-mediated protective immunity by in vivo administration of interleukin 1.
Izumi Y; Tsuchida T; Okuno K; Fujiwara H; Hamaoka T
Jpn J Cancer Res; 1985 Sep; 76(9):863-70. PubMed ID: 3932286
[TBL] [Abstract][Full Text] [Related]
4. Augmentation of antitumor immune response by trinitrophenyl (TNP)-reactive helper T-cells: enhanced induction of tumor-specific Lyt-1+2- T-cell-mediated delayed-type hypersensitivity from spleen cells of tumor-bearing mice by TNP helpers.
Suda T; Fujiwara H; Mizushima Y; Shearer GM; Hamaoka T
J Natl Cancer Inst; 1986 Dec; 77(6):1267-72. PubMed ID: 2948049
[TBL] [Abstract][Full Text] [Related]
5. The role of anti-asialo GM1 antibody-sensitive cells in the implementation of tumor-specific T cell-mediated immunity in vivo.
Yoshioka T; Sato S; Fujiwara H; Hamaoka T
Jpn J Cancer Res; 1986 Aug; 77(8):825-32. PubMed ID: 3093429
[TBL] [Abstract][Full Text] [Related]
6. Enhanced TNP-reactive helper T cell activity and its utilization in the induction of amplified tumor immunity that results in tumor regression.
Fujiwara H; Moriyama Y; Suda T; Tsuchida T; Shearer GM; Hamaoka T
J Immunol; 1984 Mar; 132(3):1571-7. PubMed ID: 6198397
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity.
Slos P; De Meyer M; Leroy P; Rousseau C; Acres B
Cancer Gene Ther; 2001 May; 8(5):321-32. PubMed ID: 11477452
[TBL] [Abstract][Full Text] [Related]
8. Effect of continuous administration of interleukin 2 on active specific chemoimmunotherapy with extracted tumor-specific transplantation antigen and cyclophosphamide.
Naito K; Pellis NR; Kahan BD
Cancer Res; 1988 Jan; 48(1):101-8. PubMed ID: 3257158
[TBL] [Abstract][Full Text] [Related]
9. Adenovirus-mediated interleukin-18 mutant in vivo gene transfer inhibits tumor growth through the induction of T cell immunity and activation of natural killer cell cytotoxicity.
Hwang KS; Cho WK; Yoo J; Seong YR; Kim BK; Kim S; Im DS
Cancer Gene Ther; 2004 Jun; 11(6):397-407. PubMed ID: 15044962
[TBL] [Abstract][Full Text] [Related]
10. A pivotal role for CC chemokine receptor 5 in T-cell migration to tumor sites induced by interleukin 12 treatment in tumor-bearing mice.
Uekusa Y; Yu WG; Mukai T; Gao P; Yamaguchi N; Murai M; Matsushima K; Obika S; Imanishi T; Higashibata Y; Nomura S; Kitamura Y; Fujiwara H; Hamaoka T
Cancer Res; 2002 Jul; 62(13):3751-8. PubMed ID: 12097285
[TBL] [Abstract][Full Text] [Related]
11. Depletion of IL-10- and TGF-beta-producing regulatory gamma delta T cells by administering a daunomycin-conjugated specific monoclonal antibody in early tumor lesions augments the activity of CTLs and NK cells.
Seo N; Tokura Y; Takigawa M; Egawa K
J Immunol; 1999 Jul; 163(1):242-9. PubMed ID: 10384122
[TBL] [Abstract][Full Text] [Related]
12. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
[TBL] [Abstract][Full Text] [Related]
13. Establishment of a tumor-specific immunotherapy model utilizing TNP-reactive helper T cell activity and its application to the autochthonous tumor system.
Fujiwara H; Aoki H; Yoshioka T; Tomita S; Ikegami R; Hamaoka T
J Immunol; 1984 Jul; 133(1):509-14. PubMed ID: 6233375
[TBL] [Abstract][Full Text] [Related]
14. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R
J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733
[TBL] [Abstract][Full Text] [Related]
15. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
16. Multiple roles of interferon-gamma in the mediation of interleukin 12-induced tumor regression.
Ogawa M; Yu WG; Umehara K; Iwasaki M; Wijesuriya R; Tsujimura T; Kubo T; Fujiwara H; Hamaoka T
Cancer Res; 1998 Jun; 58(11):2426-32. PubMed ID: 9622084
[TBL] [Abstract][Full Text] [Related]
17. Repeated restraint stress impairs the antitumor T cell response through its suppressive effect on Th1-type CD4+ T cells.
Li T; Harada M; Tamada K; Abe K; Nomoto K
Anticancer Res; 1997; 17(6D):4259-68. PubMed ID: 9494518
[TBL] [Abstract][Full Text] [Related]
18. Vaccination with B16 melanoma cells expressing a secreted form of interleukin-1beta induces tumor growth inhibition and an enhanced immunity against the wild-type B16 tumor.
Björkdahl O; Dohlsten M; Sjögren HO
Cancer Gene Ther; 2000 Oct; 7(10):1365-74. PubMed ID: 11059695
[TBL] [Abstract][Full Text] [Related]
19. Enrichment of antitumor effector cells that are effective in vivo from spleen cells of tumor-bearing mice through the use of Dolichos biflorus lectin.
Okada T; Ezawa K; Imai Y; Osawa T
Cancer Res; 1986 Nov; 46(11):5611-7. PubMed ID: 3093067
[TBL] [Abstract][Full Text] [Related]
20. Interleukin 2 activated tumor inhibition in vivo depends on the systemic involvement of host immunoreactivity.
Forni G; Giovarelli M; Santoni A; Modesti A; Forni M
J Immunol; 1987 Jun; 138(11):4033-41. PubMed ID: 2953796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]